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Interventions to improve oral vaccine performance: 
a systematic review and meta-analysis
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Summary
Background Oral vaccines underperform in low-income and middle-income countries compared with in high-income 
countries. Whether interventions can improve oral vaccine performance is uncertain.
Methods We did a systematic review and meta-analysis of interventions designed to increase oral vaccine efficacy or 
immunogenicity. We searched Ovid-MEDLINE and Embase for trials published until Oct 23, 2017. Inclusion criteria 
for meta-analysis were two or more studies per intervention category and available seroconversion data. We did 
random-effects meta-analyses to produce summary relative risk (RR) estimates. This study is registered with 
PROSPERO (CRD42017060608).
Findings Of 2843 studies identified, 87 were eligible for qualitative synthesis and 66 for meta-analysis. 22 different 
interventions were assessed for oral poliovirus vaccine (OPV), oral rotavirus vaccine (RVV), oral cholera vaccine  (OCV), 
and oral typhoid vaccines. There was generally high heterogeneity. Seroconversion to RVV was significantly increased 
by delaying the first RVV dose by 4 weeks (RR 1·37, 95% CI 1·16–1·62) and OPV seroconversion was increased with 
monovalent or bivalent OPV compared with trivalent OPV (RR 1·51, 95% CI 1·20–1·91). There was some evidence 
that separating RVV and OPV increased RVV seroconversion (RR 1·21, 95% CI 1·00–1·47) and that higher vaccine 
inoculum improved OCV seroconversion (RR 1·12, 95% CI 1·00–1·26). There was no evidence of effect for 
anthelmintics, antibiotics, probiotics, zinc, vitamin A, withholding breastfeeding, extra doses, or vaccine buffering.
Interpretation Most strategies did not improve oral vaccine performance. Delaying RVV and reducing OPV valence 
should be considered within immunisation programmes to reduce global enteric disease. New strategies to address 
the gap in oral vaccine efficacy are urgently required.
Funding Wellcome Trust, Bill & Melinda Gates Foundation, UK Medical Research Council, and WHO Polio Research 
Committee.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. 
Introduction
Despite global declines in enteric disease, approximately 
650 000 children die from diarrhoea annually,1 with 
rotavirus causing a third of deaths.2 A major obstacle to 
sustained progress is the reduced efficacy of oral vaccines 
in low-income and middle-income countries (LMICs).3 
This phenomenon was first observed for oral poliovirus 
vaccine (OPV) in the 1950s and has since been described 
for several oral vaccines in many countries. For example, 
rotavirus vaccine (RVV) efficacy against severe rotavirus 
gastroenteritis is only 39% in sub-Saharan Africa4 and 
48% in south Asia,5 compared with 85–98% in Europe 
and the USA.6,7 The reasons for oral vaccine under-
performance are unclear.8 Potential explanations include 
concurrent enteric infections,9,10 microbiota composition,11 
environmental enteric dysfunction,12 interference from 
maternal antibodies,13,14 histoblood group antigens,15 and 
micronutrient deficiencies.16,17 The relative contributions 
of these factors can vary depending on oral vaccine target, 
recipient age, and setting.
Multiple studies have assessed interventions to 
improve oral vaccine performance, broadly categorised 
as adjunctive interventions given before or with 
vaccination (such as micronutrient supplements or 
antimicrobials) or adjustments to the vaccine formulation 
and delivery schedule (such as increased vaccine 
inoculum or altered timing). Reviews have assessed 
specific interventions18 or individual vaccines,19,20 but 
none have assessed the full range of approaches used 
across all oral vaccines. We therefore did a systematic 
review and meta-analysis of interventions to increase oral 
vaccine efficacy or immunogenicity in LMICs.
Methods
Search strategy and selection criteria
We followed PRISMA guidelines throughout our review. 
We searched Ovid-MEDLINE and Embase for English 
language articles published any time up to Oct 23, 2017, 
describing studies assessing interventions to improve oral 
vaccine performance (appendix p 2). We examined the 
reference lists of articles to identify additional studies, 
searched the grey literature, and contacted experts for 
unpublished data.
We screened full-text papers for inclusion in the 
qualitative synthesis. We included randomised trials, 
cluster-random ised trials, non-randomised trials, and 
See Online for appendix
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meta-analyses assessing one or more interventions. We 
did not include case-control studies, controlled before–
after studies, or observational data from cross-sectional 
studies and case series. Studies were excluded if they 
included fewer than ten participants, did not include a 
control group, or did not measure vaccine efficacy or 
immunogenicity. We excluded strategies bypassing the 
oral route (eg, use of inactivated poliovirus vaccine), and 
pre-licensure dose-finding trials. We did not exclude 
studies on the basis of participant age or setting, because 
studies from high-income countries or in older age 
groups might provide insights into oral vaccine failure 
among infants in LMICs. For meta-analysis, inclusion 
criteria required two or more studies per intervention 
category and available seroconversion data. The 
protocol is available at www.crd.york.ac.uk/PROSPERO, 
CRD42017060608.
Outcome definitions
The prespecified primary outcome was oral vaccine 
performance, defined as either vaccine efficacy or 
immunogenicity, depending on study design. Vaccine 
efficacy was defined as percentage disease reduction in 
the vaccinated group compared with the unvaccinated 
group. Our prespecified preferred measure of vaccine 
immunogenicity was the proportion of children with 
seroconversion, as defined by each study, after the last 
scheduled vaccine dose. Alternative measures included 
geometric mean titres and fold-rise if seroconversion 
was not reported (appendix p 8). Studies without 
seroconversion data were included in the qualitative 
synthesis but were not eligible for meta-analysis. 
Timing of vaccine immunogenicity measure ment was 
not considered in the eligibility criteria. The chosen 
correlates of protection were serum neutralising 
antibodies for OPV, serum IgA for RVV, and vibriocidal 
antibodies for oral cholera vaccine (OCV).
Data analysis
Two independent reviewers (JAC and EPP) assessed 
eligibility of each full-text article; a third (AJP) arbitrated 
for cases without consensus. One reviewer (JAC) 
extracted data, and a second (EPP) validated data 
extraction for 10% of studies. Descriptive and quantitative 
data were entered into a spreadsheet based on the 
Cochrane data extraction tool.21 If more than one 
intervention or oral vaccine were reported in the same 
study, data were extracted separately for each. For studies 
with a factorial design, data were only extracted from the 
combined group if there was no interaction between 
interventions, otherwise data from individual groups 
were used. Where numerical data were not reported, we 
requested data from authors or used GetData Graph 
Digitiser to extract results from figures. We assessed 
Research in context
Evidence before this study
Oral vaccines consistently underperform when given to children 
in low-income and middle-income countries (LMICs) but the 
underlying causes and potential intervention approaches are 
unclear. We searched Ovid-MEDLINE and Embase for systematic 
reviews and meta-analyses of interventions to improve oral 
vaccine performance published up to May 31, 2018, using the 
same search strategy detailed in the appendix (p 5). We identified 
three systematic reviews, one including a meta-analysis. The 
meta-analysis, published in 1998, found that regimens 
containing a single dose of typhoid vaccine were less effective 
than were regimens with two or more doses. Of the remaining 
two systematic reviews, both published in 2017, one examined 
differences in rotavirus vaccine scheduling across eight trials, 
concluding that seroconversion was lower among children given 
the vaccine earlier in infancy (age 6 and 10 weeks) versus later in 
infancy (age 10 and 14 weeks). The other, restricted to probiotics, 
found a beneficial effect of probiotics on vaccine responses 
(parenteral and oral vaccines) in half of the studies. However, 
there have been no systematic reviews assessing all intervention 
strategies (both adjunctive and vaccine design or delivery 
adjustments) across oral poliovirus, rotavirus, cholera, and 
typhoid vaccines. We assessed the full range of intervention 
approaches and oral vaccines investigated to date, to identify 
whether any strategies could be adopted by immunisation 
programmes, and to identify research gaps to inform future trials.
Added value of this study
This is the first systematic review and meta-analysis of 
approaches to improve oral vaccine performance among 
children. We assessed the evidence for 22 interventions 
targeting four oral vaccines. Overall, we found few 
interventions had a substantial benefit on the basis of the 
available evidence, highlighting the challenge in overcoming 
oral vaccine underperformance. However, we found that 
delaying the first dose of rotavirus vaccine and reducing oral 
poliovirus vaccine valence can improve oral vaccine 
immunogenicity.
Implications of all the available evidence
Existing oral vaccines and their schedules are poorly effective 
among children in LMICs. Most adjunctive interventions to date 
have not improved oral vaccine performance. Untested 
interventions such as water, sanitation and hygiene, the effect 
of booster doses given later in infancy, and increasing vaccine 
inoculum for rotavirus vaccine warrant further study. Cost-
benefit and modelling analyses that consider the full effect of 
delaying the first dose of rotavirus vaccine should be 
undertaken. However, the global research community should 
also strongly consider new and innovative ways to address this 
efficacy gap, including a decreased reliance on oral vaccines, to 
reduce the global burden of enteric disease.
For the protocol see 
www.crd.york.ac.uk/PROSPERO
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quality of evidence for each study using Grading of 
Recommendations, Assessment, Development and 
Evaluation (GRADE) criteria22 (appendix p 9).
To assess the effect of each intervention on sero-
conversion, we did random-effects meta-analyses in the 
R package metafor.23 We calculated summary relative risk 
(RR) estimates and 95% CIs for each vaccine evaluated in 
two or more studies. If more than one vaccine was asses-
sed for a given intervention, we did a pooled analysis 
combining across vaccines, and a mixed-effects analysis 
with vaccine type as a moderator. For mixed-effects 
models, we identified whether heterogeneity associated 
with vaccine type or residual heterogeneity was 
significant via χ² tests.24 If residual heterogeneity was 
significant (p<0·05), we assessed age, setting, and 
background immunogenicity (seroconversion rate in the 
control group) as secondary moderators. We used funnel 
plots to check for publication bias and tested for 
asymmetry using Egger’s test. Further details of the 
analysis are provided in the appendix (p 10). All analyses 
were done in R (version 3.4.1).
Role of the funding source
The funder had no role in study design, data collection, 
data analysis, data interpretation, or writing of the report. 
The corresponding author had full access to all data in 
the study and had final responsibility for the decision to 
submit for publication.
Results
Of 2843 articles, 87 were eligible for qualitative synthesis 
(figure 1). The studies are summarised in the table and 
the full dataset is available online. 74 (85·1%) were 
randomised trials and 13 (14·9%) non-randomised trials. 
The studies were done in 38 countries between 1972 and 
2017 (appendix p 11) and enrolled between 30 and 
225 998 participants (median 301, IQR 128–718). 
11 studies (12·6%) were done in adults.
22 interventions were assessed (14 adjunctive inter-
ventions and eight vaccine design or delivery inter-
ventions), grouped into 17 categories: anthelmintic 
therapy (n=3), antibiotic therapy (n=1), probiotic 
supplementation (n=6), zinc supplementation (n=6), 
vitamin A supplementation (n=6), other micronutrient 
supplementation (n=3), withholding breastfeeding (n=6), 
extra dose or doses (n=10), extra dose given at birth (n=6), 
early first dose (n=1), delayed first dose (n=4), shortened 
interval between doses (n=5), RVV given with versus 
without OPV (n=7), increased vaccine inoculum (n=11), 
different OPV valences (n=10), inclusion of buffer (n=11), 
and miscellaneous (n=4, appendix p 4). No studies of 
water, sanitation, or hygiene interventions were found. 
12 studies included more than one intervention, of which 
two employed a factorial design (appendix p 12). OPV 
was the most common vaccine studied (46 studies, 
52·9%), followed by RVV (n=24, 37·6%), OCV (n=15, 
17·2%), and oral typhoid vaccine (n=9, 10·3%).
Of the 87 studies, 66 (from 13 intervention categories) 
were eligible for inclusion in the meta-analysis (table). 
Eight studies (9∙3%) included in the qualitative synthesis 
reported vaccine efficacy as the primary outcome. Most 
studies (n=66, 75·9%) reported vaccine seroconversion 
as the primary outcome. Additional immunogenicity 
characteristics are described in the appendix (p 13).
GRADE scoring is reported in the full dataset. 
11 studies (12·6%) had a low risk of bias across all 
2843 articles yielded from initial search
1445 MEDLINE (last updated Oct 19, 2017)
1398 Embase (last updated Oct 23, 2017)
1647 records screened
263 abstracts screened
111 articles included for full-text screening
66 articles included in meta-analysis
87 articles included in qualitative synthesis*
15 micronutrients
1 antibiotic
6 probiotic
3 anthelmintic
6 withholding breastfeeding
44 dosing
10 OPV valence
11 buffer
4 miscellaneous
1196 articles excluded after removal of duplicates
6 articles included after search of grey literature 
and correspondence with experts in field
1384 articles excluded after scanning titles
165 articles excluded after scanning abstracts
24 articles excluded after full-text screening
5 duplicate material
6 no intervention
6 no appropriate control group
4 no measure of vaccine response
2 unable to retrieve data
1 ineligible study type
7 articles included after scanning reference lists 
from selected articles
21 articles did not report seroconversion as the      
      primary outcome
Figure 1: Study selection
OPV=oral polio vaccine. *Studies exploring multiple interventions are duplicated within this breakdown.
For the full dataset see 
https://osf.io/bemw6/
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domains of study quality, 76 (87·4%) had an unclear risk 
of bias in at least one domain, and 42 (48·3%) had a high 
risk of bias in two or more domains (appendix p 14). 
30 studies were downgraded during GRADE assessment 
for indirectness, mostly because of poor generalisability 
(ie, not studying children or not done in an LMIC). 
Potential publication bias, assessed using funnel plots, 
was identified in seven intervention categories 
(appendix p 26).
Six randomised controlled trials reported oral vaccine 
seroconversion following vitamin A supplementation. 
Among five studies eligible for meta-analysis (four on 
OPV, one on OCV), there was no significant effect of 
vitamin A supplementation on seroconversion (overall 
RR 1·01, 95% CI 0·99–1·03). There were six studies of 
zinc supplementation, of which five were included in the 
meta-analysis (three on OCV, one on RVV, and one on 
OPV). Overall, there was no significant effect of zinc 
supplementation on seroconversion (1·11, 95% CI 
0·87–1·42; figure 2). A factorial trial in Bangladesh 
reported an interaction between vitamin A and zinc 
supplementation, whereby zinc combined with vitamin A 
increased seroconversion to OCV more than zinc alone.25 
Single studies reported several other micronutrient 
interventions. There was no evidence that vitamin A 
given to mothers post partum,26 selenium capsules,27 or 
oral iodine28 had an effect on OPV immunogenicity, and 
giving multiple micronutrients had no effect on response 
to oral typhoid vaccine.29
Six studies assessed withholding breastfeeding for 
1–10 h (mean 3·5, SD 3·4) around the time of oral 
vaccination; five were eligible for meta-analysis (one on 
OCV, three on RVV, one on OPV). There was no evidence 
of benefit for seroconversion to OCV, RVV, or OPV 
(overall RR 0·93, 95% CI 0·75–1·14; appendix p 15).
Six studies reported probiotic interventions, of which 
four were eligible for meta-analysis (one on OCV, two on 
RVV, one on OPV). In each study, daily probiotics were 
started 7 days before vaccination and continued for at 
least 3 weeks after; three studies used lactobacillus30–32and 
one used bifidobacterium.33 There was no evidence of an 
effect on seroconversion to OCV, RVV, or OPV (overall 
RR 1·09, 95% CI 0·84–1·41; figure 2).
32 studies reported changes in vaccine formulation 
(addition of a buffer, increased inoculum, or altered OPV 
valence); 28 were eligible for meta-analysis (eight on 
buffer, 11 on inoculum, nine on OPV valence). There was 
weak evidence that adding buffer increased serocon-
version to OCV (RR 1·32, 95% CI 0·98–1·78), although 
there were few participants (n=219). Two typhoid studies 
showed increased vaccine efficacy when reconstituted in 
buffer compared with a capsule control.34,35 Overall, when 
combining data for all vaccines, there was weak evidence 
of improved seroconversion with buffer (1·03, 95% CI 
0·98–1·09; appendix p 16). Increases in vaccine inoculum 
showed some evidence of benefit for seroconversion 
across four studies for OCV (1·12, 1·00–1·26), but not for 
OPV (1∙02, 0∙95–1∙09; figure 2). Nine studies exploring 
adjustments to OPV valence were included in the meta-
analysis; seven used monovalent OPV and two used 
bivalent OPV. Compared with trivalent OPV, monovalent 
and bivalent OPV significantly increased seroconversion 
(1·51, 95% CI 1·20–1·91), with a consistent effect across 
OPV1 and OPV3 (appendix p 19).
Oral poliovirus 
vaccine
Oral rotavirus 
vaccine
Oral cholera 
vaccine
Oral typhoid 
vaccine
Total studies (n)* 46 24 15 9
Intervention
Anthelmintic 0 0 2 1
Antibiotic† 1 0 0 0
Breastfeeding withheld 2 3 1 0
Buffer 1 4 3 3
Delayed first dose 0 4 0 0
Early first dose† 1 0 0 0
Extra dose or doses 1 6 1 2
Extra dose at birth 5 1 0 0
Miscellaneous† 3 0 1 0
Narrow dose interval 3 1 0 1
OPV valence 10 NA NA NA
Other micronutrients† 2 0 0 1
Probiotic 1 2 2 1
RVV separated from OPV 7 7 NA NA
Vaccine inoculum 7 0 4 0
Vitamin A 4 0 1 1
Zinc 1 1 4 0
Age group
<1 month 19 1 0 0
1–12 months 24 23 3 0
1–15 years 2 0 4 6‡
≥16 years 1 0 8 3
Mean age (SD; months) 4·2 (7·9) 1·9 (1·3) 141·6 (163·3) 187·9 (133·8)
Sex
Men (%) 51·3 45·7 50·5 55·9
Women (%) 48·7 54·3 49·5 44·1
Location
Africa 8 6 2 1
Asia 25 10 7 2
Europe 5 3 2 2
Americas 8 4 4 4
Oceania 0 1 0 0
Study size
<50 7 1 2 2
50–500 37 21 13 2
>500 2 2 0 5
Total seroconversion data (n) 8838 8954 1395 353 030
RVV=oral rotavirus vaccine. OPV=oral poliovirus vaccine. *Of 87 unique studies, some studies examined two or more 
interventions and some reported on multiple oral vaccine targets (appendix p 12). †There were insufficient studies 
(fewer than two) of antibiotics, early first dose, other micronutrients, and miscellaneous interventions (maternal 
vitamin A, horse anti-serum, soya formula, and Escherichia coli K-12) for inclusion in the meta-analysis. ‡Most typhoid 
studies recruited children aged between 5 and 22 years.
Table: Overview of 87 intervention studies included in the systematic review
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Zinc
Country Age (months) Vaccine Intervention n/N (%) Control n/N (%) RR (95% CI)
Cholera
Ahmed (January, 2009)
Ahmed (January, 2009)
Ahmed (October, 2009)
Albert (2003)
Summary
Rotavirus
Lazarus (2017)
OPV3
Habib (2015)
Overall
Heterogeneity among vaccines (Qm 0·15, df 2), p=0·927; residual heterogeneity (Qe 10·97, df 3), p=0·012
Bangladesh
Bangladesh
Bangladesh
Bangladesh
India
Pakistan
7·5
14
14
40
1·2
0·3
2× Wc-rBS
2× Wc-rBS
2× Wc-rBS
2× Cholerix
2× RV1
4× tOPV
Zinc (20 mg)
Zinc (20 mg)
Zinc (20 mg)
Zinc (20 mg)
Zinc (5 mg)
Zinc (10 mg)
No zinc
No zinc
No zinc
Placebo
Placebo
Placebo
27/47 (57%)
27/49 (55%)
11/20 (55%)
29/63 (46%)
37/135 (46%)
99/163 (61%)
0·53 (0·31–0·92)
1·44 (1·06–1·96)
1·52 (0·97–2·37)
1·34 (0·97–1·87)
1·16 (0·75–1·79)
1·02 (0·70–1·49)
0·99 (0·83–1·18)
1·11 (0·87–1·42)
11/36 (31%)
27/34 (79%)
15/18 (83%)
39/63 (62%)
40/143 (28%)
94/156 (60%)
1·00·33 3·0
Probiotic
Cholera
Matsuda (2011)
Rotavirus
Isolauri (1995)
Lazarus (2017)
Summary
OPV3
DeVrese (2005)*
Overall
Heterogeneity among vaccines (Qm 7·35, df 2), p=0·025; residual heterogeneity (Qe 0·22, df 1), p=0·639
Bangladesh
Finland
India
Germany
44·1
4·1
1·2
Adult
2× Wc-rBS
1× DxRRV
1× RV1
1× OPV3
Bbb01 (109)
Lc ATCC
LGG
LGG
Placebo
Placebo
Placebo
Placebo
47/62 (76%)
20/27 (74%)
37/135 (27%)
8/22 (36%)
0·82 (0·65–1·04)
1·25 (0·98–1·60)
1·13 (0·78–1·64)
1·21 (0·99–1·49)
1·57 (0·81–3·06)
1·09 (0·84–1·41)
40/64 (63%)
26/28 (93%)
42/136 (31%)
12/21 (57%)
1·00·33 3·0
OPV valence
OPV3
Asturias (2016)
Patriarca (1988)
Saleem (2017)
Sutter (2000)
Sutter (2010)§
Waggie (2012)
Summary
Heterogeneity (Qe 97·20, df 5), p<0·001
Multiple
Brazil
Pakistan
Oman
India
South Africa
1·4
9·6
0
9
0
0
3× OPV
1× OPV
4× OPV
1× OPV
2× OPV
1× OPV
bOPV
mOPV3
bOPV
mOPV3
mOPV3
mOPV3
tOPV
tOPV
tOPV
tOPV
tOPV
tOPV
87/88 (99%)
13/83 (16%)
114/134 (85%)
155/177 (88%)
87/168 (52%)
39/184 (21%)
1·00 (0·97–1·02)
3·31 (1·93–5·70)
1·10 (1·01–1·20)
1·05 (0·98–1·13)
1·63 (1·39–1·91)
2·73 (2·02–3·70)
1·54 (1·04–2·28)
195/198 (98%)
41/79 (52%)
135/144 (94%)
189/205 (92%)
139/165 (84%)
113/195 (58%)
1·00·75 4·0
Increased vaccine inoculum
Cholera
Gotuzzo (1993)
Sow (2017)
Su-Arehawaratana (1992)
Suharyono (1992)
Suharyono (1992)
Summary
OPV3
Agarwal (1991)
Chopra (1989)
Jhala (1981)
Patriarca (1988)
WHO (1995)
WHO (1995)
Summary
Overall
Heterogeneity among vaccines (Qm 2·08, df 1), p=0·149; residual heterogeneity (Qe 14·84, df 9), p=0·096
Peru
Mali
Thailand
Indonesia
Indonesia
India
India
India
Brazil
Brazil
Gambia
Adult
Adult
Adult
60–108
60–108
6–12
1–12
3–36
9·6
0
0–1·5
1× CVD103-HgR
1× CVD103-HgR
1× CVD103-HgR
1× CVD103-HgR
1× CVD103-HgR
3× tOPV
5× tOPV
3× tOPV
1× tOPV
4× tOPV
4× tOPV
High (109)
High (2x109)
High (5x109)
High (1010)
High (1010)
High (0·2 mL)
High (0·4 mL)
High (0·4 mL)
High (6x105)
High (6x105)†
High (6x105)‡
Std (108)
Std (2x108)
Std (5x108)
Std (5x109)
Std (5x109)
Std (0·1 mL)
Std (0·2 mL)
Std (0·2 mL)
Std (3x105)
Std (3x105)
Std (3x105)
19/39 (49%)
33/46 (72%)
13/39 (33%)
27/31 (87%)
21/28 (75%)
24/42 (57%)
33/34 (97%)
49/87 (56%)
13/83 (16%)
111/176 (63%)
111/159 (70%)
1·47 (1·01–2·15)
1·16 (0·93–1·45)
1·28 (0·72–2·26)
1·04 (0·88–1·24)
1·08 (0·83–1·42)
1·12 (1·00–1·26)
1·05 (0·72–1·53)
0·99 (0·91–1·09)
0·99 (0·67–1·47)
2·71 (1·54–4·78)
1·02 (0·87–1·19)
1·02 (0·89–1·18)
1·02 (0·95–1·09)
1·05 (0·99–1·11)
28/39 (72%)
40/48 (83%)
17/40 (43%)
30/33 (91%)
26/32 (81%)
21/35 (60%)
27/28 (96%)
14/25 (56%)
31/73 (42%)
125/195 (64%)
151/161 (71%)
1·00·50 4·0
Figure 2: Effect of adjuncts or vaccine composition on seroconversion to oral vaccines
Forest plot showing the effects of zinc supplementation, probiotics, increased vaccine inoculum, and OPV valence on seroconversion to OCV, RVV, or OPV. Bbb01=Bifidobacterium breve 01. 
Lc ATCC=Lactobacillus casei ATCC. LGG=lactobacillus GG. OPV=oral poliovirus vaccine. bOPV=bivalent OPV. mOPV=monovalent OPV. tOPV=trivalent OPV. RVV=rotavirus vaccine. RV1=Rotarix monovalent 
vaccine. Qm=Q statistic for moderator effect.  *This study also examined another probiotic, Lactobacillus casei, with similar results. We excluded these data from the forest plot to avoid replication of the 
control group. †This study also included an arm comparing bOPV with tOPV. We excluded these data from the forest plot to avoid replication of the control group. 
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19 studies investigated changes to vaccine dosing; 
14 were eligible for meta-analysis, assessing additional 
doses (n=8; one on OCV, six on RVV, one on OPV) or 
additional birth dosing (n=6; five on OPV, one on RVV). 
There was weak evidence that increasing the number of 
doses improved seroconversion (RR 1·12, 95% CI 
Delayed first dose
Country Age (months) Vaccine Intervention n/N (%) Control n/N (%) RR (95% CI)
Rotavirus
Ali (2014)
Anh (2011)
Armah (2016)
Steele (2010)*§
Steele (2010)*§
Summary
Heterogeneity (Q 5·73, df 4), p=0·220
Pakistan
Phillippines
Ghana
South Africa
South Africa
1·4
2
1·4
1·5
1·5
2χ RV1
2χ RV1
2χ RV1
2χ RV1 + OPV
2χ RV1 + IPV
Late (10, 14 weeks)
Late (11, 15 weeks)
Late (10, 14 weeks)
Late (10, 14 weeks)
Late (10, 14 weeks)
Std (6, 10 weeks)
Std (7, 15 weeks)
Std (6, 10 weeks)
Std (6, 10 weeks)
Std (6, 10 weeks)
46/155 (30%)
71/120 (59%)
29/142 (20%)
24/67 (36%)
28/65 (43%)
1·30 (0·95–1·77)
1·18 (0·98–1·43)
1·83 (1·24–2·70)
1·71 (1·16–2·53)
1·27 (0·88–1·85)
1·37 (1·16–1·62)
60/156 (38%)
84/120 (70%)
52/139 (37%)
30/49 (61%)
28/51 (55%)
1·00·33 3·0
Extra dose or doses
Cholera
Su-Arehawaratana (1992)
Rotavirus
Ali (2014)
Armah (2016)
Kompithra (2014)
Lanata (1989)
Madhi (2010)¶
Madhi (2010)¶
Steele (JID 2010)
Summary
OPV3
Jhala (1981)
Overall
Heterogeneity among vaccines (Qm 8·49, df 2), p=0·014; residual heterogeneity (Qe 6·58, df 6), p=0·361
Thailand
Pakistan
Ghana
India
Peru
Malawi
South Africa
South Africa
India
Adult
1·4
1·4
1·4–1·6
2–18
1·4
1·4
1·6
3–36
CVD103-HgR
RV1
RV1
RV1
RIT4237
RV1
RV1
RV1
tOPV
2 doses
6, 10, 14 weeks
6, 10, 14 weeks
6, 10, 14, 18, 22 weeks
3 doses
6, 10, 14 weeks
6, 10, 14 weeks
6, 10, 14 weeks
≤6 doses
 1 dose
10, 14 weeks
10, 14 weeks
6, 10, 14 weeks
1 dose
10, 14 weeks
10, 14 weeks
10, 14 weeks
3 doses
17/40 (43%)
60/156 (39%)
52/139 (37%)
15/44 (34%)
20/75 (27%)
20/42 (47%)
40/70 (57%)
58/131 (44%)
49/87 (56%)
1·35 (0·86–2·12)
0·95 (0·72–1·26)
1·16 (0·87–1·54)
0·80 (0·42–1·51)
0·53 (0·27–1·05)
1·20 (0·80–1·81)
1·17 (0·90–1·52)
1·00 (0·76–1·31)
1·04 (0·92–1·18)
1·54 (1·21–1·97)
1·12 (0·96–1·30)
23/40 (58%)
62/169 (37%)
62/143 (43%)
52/139 (37%)
10/71 (14%)
24/42 (57%)
44/66 (67%)
59/133 (44%)
20/23 (87%)
1·00·33 3·0
Extra dose at birth
Rotavirus
Bines (2015)
OPV3
DeXiang (1986)
Jain (1997)
Khare (1993)
Osei-Kwasi (1995)
Weckx (1992)
Summary
Overall
Heterogeneity among vaccines (Qm 0·61, df 1), p=0·436; residual heterogeneity (Qe 8·81, df 4), p=0·066
New Zealand
China
India
India
Ghana
Brazil
0·1
0·1
0
0
0
0
RV3-BB
tOPV
tOPV
tOPV
tOPV
tOPV
3 doses
4 doses
4 doses
4 doses
4 doses
4 doses
2 doses
3 doses
3 doses
3 doses
3 doses
3 doses
15/20 (75%)
106/107 (99%)
14/30 (47%)
32/41 (78%)
155/196 (79%)
20/27 (74%)
0·92 (0·64–1·32)
1·01 (0·98–1·04)
1·54 (0·98–2·43)
1·11 (0·90–1·38)
1·05 (0·95–1·15)
1·30 (1·03–1·64)
1·08 (0·99–1·18)
1·06 (0·98–1·14)
18/26 (69%)
107/107 (100%)
18/25 (72%)
26/30 (87%)
166/200 (83%)
26/27 (96%)
1·00·75 2·0
RVV separated from OPV
Rotavirus
Ciarlet (2008)
Giammanco (1988)
Hanlon (1987)
Migasena (1995)
Steele (2010)§
Steele (2010)§
Vodopija (1986)
Zaman (2009)
Summary
OPV3
Ciarlet (2008)
Giammanco (1988)
Hanlon (1987)
Steele (2010)
Vodopija (1986)
Zaman (2009)
Summary
Overall
Heterogeneity among vaccines (Qm 8·20, df 1), p=0·004; residual heterogeneity (Qe 24·20, df 12), p=0·019
Multiple
Italy
Gambia
Thailand
South Africa
South Africa
Yugoslavia
Bangladesh
Multiple
Italy
Gambia
South Africa
Yugoslavia
Bangladesh
2
3
2·5
2–6
1·5
1·5
3
1·4
2
3
2·5
1·5
3
1·4
3χ RV5
1χ RIT4237
3χ RIT4237
3χ RRV-TV
RV1 (6, 10 weeks)
RV1 (10, 14 weeks)
1χ RIT4237
2χ RV1
3χ tOPV
1χ tOPV
3χ tOPV
2χ tOPV
1χ tOPV
3χ tOPV
Without OPV
With placebo
With IPV
With placebo
With placebo
With placebo
With placebo
Without OPV
Without RVV
With placebo
With placebo
With placebo
With placebo
Without RVV
With OPV
With OPV
With OPV
With OPV
With OPV
With OPV
With OPV
With OPV
With RVV
With RVV
With RVV
With RVV
With RVV
With RVV
343/368 (93%)
2/23 (9%)
38/86 (44%)
15/89 (17%)
24/67 (36%)
30/49 (61%)
10/38 (26%)
39/69 (57%)
362/368 (98%)
6/23 (26%)
45/87 (52%)
49/50 (98%)
11/29 (38%)
48/69 (70%)
1·05 (1·02–1·08)
6·71 (1·71–26·31)
1·05 (0·77–1·45)
1·63 (0·92–2·88)
1·20 (0·79–1·84)
0·90 (0·64–1·25)
2·49 (1·37–4·51)
1·18 (0·90–1·t54)
1·21 (1·00–1·47)
1·00 (0·98–1·02)
2·01 (0·90–4·47)
1·16 (0·89–1·51)
1·00 (0·95–1·06)
0·96 (0·50–1·83)
0·88 (0·65–1·19)
1·00 (0·98–1·02)
1·01 (1·00–1·03)
319/326 (98%)
14/24 (58%)
46/99 (46%)
25/91 (27%)
28/65 (43%)
28/51 (55%)
19/29 (66%)
44/66 (67%)
321/126 (98%)
11/21 (52%)
57/95 (60%)
61/62 (99%)
12/33 (36%)
22/36 (61%)
1·00·25 4·0
Articles
www.thelancet.com/infection   Vol 19   February 2019 209
0·96–1·30; figure 3). Two studies reporting RVV efficacy 
as the primary outcome also showed weak evidence of 
benefit in increasing from two to three doses.36,37 There 
was weak evidence that an additional birth dose of 
OPV increased OPV3 seroconversion (RR 1·08, 95% CI 
0·99–1·18), and findings remained similar in the 
combined meta-analysis, which included a rotavirus 
study38 (1·06, 95% CI 0·98–1·14; appendix p 17).
17 studies reported altered timing of vaccine 
administration (five narrowed dose interval, four delayed 
first dose, one early first dose, and seven staggered RVV 
and OPV administration); 15 were eligible for meta-
analysis. We found no evidence that narrowing the 
dosing interval (from 4–8 weeks to 1–4 weeks, assessed in 
one study of RVV, two of OPV) benefited seroconversion 
(RR 0·98, 95% CI 0·94–1·02; appendix p 19), although 
these trials were primarily designed as non-inferiority 
studies. Conversely, delaying the first dose of RVV by 
4 weeks (four studies) significantly increased serocon-
version rates (1·37, 1·15–1·61; figure 3). We found no 
evidence that staggered administration of RVV and OPV 
affected OPV seroconversion (1·00, 0·98-1·02), with 
consistent findings across all OPV serotypes (appendix p 
21). By contrast, there was some evidence that children 
given RVV alone or separated from OPV were more 
likely to seroconvert against rotavirus compared with 
children given RVV and OPV concomitantly (1·21, 
95% CI 1·00–1·47; figure 3).
Three studies examined the effect of anthelmintics on 
oral vaccine responses39–41 with no overall effect on 
seroconversion to OCV (RR 1·26, 95% CI 0·63–2·53) or 
typhoid (appendix p 15). Only one antibiotic study was 
identified.42 This randomised controlled trial found no 
effect of oral azithromycin on OPV immuno genicity, 
although antibiotics reduced faecal biomarkers of 
environmental enteric dysfunction. There was no evidence 
that soy-based formulas,43 compared with human milk or 
conventional formula, affected OPV immunogenicity. 
One study of anti-human γ-globulin horse serum and 
another of inactivated Escherichia coli K12 showed a 
positive effect on OPV and OCV responses, respectively;44,45 
however, both were downgraded in GRADE assessment to 
a score of one or less (very low quality evidence) on the 
basis of study quality and indirectness.
Overall, there was considerable heterogeneity between 
studies. For three interventions (extra dose or doses, 
probiotics, and separating RVV from OPV), the 
intervention effect differed significantly according to 
vaccine type (appendix p 26); for four interventions 
(breastfeeding, OPV valence, separating RVV from 
OPV, and zinc), there was significant residual 
heterogeneity not explained by vaccine type (appendix 
p 26). For zinc, the effect on vaccine response was 
significantly greater for older than for younger children 
(appendix p 27). For OPV valence and separating RVV 
from OPV, background immunogenicity was negatively 
correlated with in- tervention effect (appendix p 27). 
Notably, the beneficial effect of staggered administration 
for RVV seroconversion was strongest in two studies 
with low background immunogenicity that administered 
only a single dose of RVV.46,47 For withholding 
breastfeeding, neither age, setting, nor background 
immunogenicity were sig-nificant secondary moderators 
(appendix p 27).
Because of variation in timing of post-vaccine titre 
measurements, we did a sensitivity analysis, excluding 
19  studies that measured seroconversion outside our 
prespecified windows (appendix p 8). The inferences for 
each intervention remained unaltered in meta-analysis 
(appendix p 28).
Summary effect sizes for each meta-analysis, grouped 
by vaccine, are shown in figure 4. Overall, RRs for 
seroconversion across all interventions ranged between 
0·93 and 1·54. For OCV, there was weak evidence 
that all interventions (except probiotics) improved 
seroconversion. For RVV, delayed administration of the 
first dose was the most effective intervention; there was 
some evidence that staggered RVV and OPV and 
probiotics increased RVV seroconversion. For OPV, 
adjusting valence was the most effective intervention. 
Extra doses of OPV were also effective in one small 
study.48
Discussion
Oral vaccine underperformance is a major public health 
problem in LMICs. In this systematic review, we identified 
87 studies assessing interventions aimed at improving 
oral vaccine immunogenicity, done over the past 
four decades. Typically, there were few studies for a given 
intervention and effect sizes were small. Delayed RVV 
administration and altered OPV valence were the only 
effective approaches identified from the available 
evidence.
Our finding that delaying the first dose of RVV 
improves seroconversion is consistent with another 
Figure 3: Effect of dosing on seroconversion to oral vaccines
Forest plot showing the effects of delaying the first dose, separating RVV from 
OPV, and giving extra doses on seroconversion to OCV, OPV, or RVV. 
IPV=inactivated poliovirus vaccine. OPV=oral poliovirus vaccine. 
bOPV=bivalent OPV. mOPV=monovalent OPV. tOPV=trivalent OPV. 
RVV=rotavirus vaccine. RV1=Rotarix monovalent vaccine. RV5=RotaTeq 
pentavalent vaccine. Qe=Q statistic for residual heterogeneity. Qm=Q statistic 
for moderator effect. *Intervention and control group recruited separately. 
†Centrifuged. ‡Filtered. §Exact sample sizes were not reported for 
immunogenicity data and were therefore estimated by assuming that 
loss-to-follow-up rates reported in figure 1 of the trial report were evenly 
distributed across groups. ‡Study included both a 6-week plus 10-week dose 
schedule and a 10-week plus 14-week dose schedule. The 10-week plus 
14-week schedule was selected as the control group to ensure consistency with 
other studies and to delineate the effect of extra doses from delayed doses 
(considered in a separate comparison). ¶Immunogenicity data extracted from 
Madhi et al145 and Cunliffe et al.146 Exact sample sizes were not reported for 
Malawi data; we therefore assumed that the 85 RVV recipients were distributed 
1:1 across the 2-dose and 3-dose schedules (n=42 per group) and used the 
reported seroconversion rates (47·2% and 57·1%) to estimate the number of 
infants who seroconverted.
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systematic review.19 The mechanism for increased 
immunogenicity when RVV is delayed is probably a 
combination of less interference from maternal 
antibodies49 and maturation of infant immune function.50 
Delayed RVV administration might also mitigate the 
inhibitory effect of OPV; for example, we found some 
evidence (driven primarily by studies involving a single 
RVV dose) that concurrent administration of OPV and 
RVV leads to lower seroconversion to RVV, consistent 
with in-vitro observations.51 The decision to delay 
administration of RVV on the basis of our findings 
should be weighed against the risks of postponing 
protection against early natural infection, which might 
increase the risk of severe disease. It would be useful to 
compare the frequency and severity of infections and 
cost-effectiveness between the current approach and a 
delayed strategy using modelling, to better inform 
scheduling decisions. Reducing OPV valence also 
showed clear evidence of benefit for seroconversion. 
Enhanced immunogenicity of monovalent or bivalent 
OPV compared with trivalent OPV reflects the inhibitory 
effect of Sabin 2 vaccine virus on the uptake of other 
serotypes. This finding suggests that the switch from 
trivalent OPV to bivalent OPV (which does not contain 
Sabin 2 virus) in 2016—motivated primarily by the need 
to mitigate the risk of vaccine-derived poliovirus 
out breaks52—has probably improved immunity to 
seretypes 1 and 3.
Several interventions showed weak evidence of benefit, 
but effect sizes were generally small and the lower bound 
of the 95% CI did not exclude unity. There was weak 
evidence of increased seroconversion with oral vaccine 
buffering, which is designed to protect key components 
from destruction by gastric acid. However, administering 
oral vaccines that incorporate sufficient buffer can be 
challenging in young children, and there might be a 
reduced effect in this age group because they have little 
gastric acid.
We found some evidence that increasing vaccine 
inoculum improved seroconversion to OCV, but not to 
OPV. For OCV, increasing the inoculum from 1 × 10⁸ to 
1 × 10⁹ colony-forming units (CFUs) modestly improved 
seroconversion rates (RRs of 1·16–1·47), while further 
increases (from 5 × 10⁹ to 1 × 10¹⁰ CFUs) did not confer 
any additional benefit.53 Together, these findings sug-
gest that OCV immunogenicity might plateau as the 
administered dose increases. OPV already contains more 
than 1 × 10⁵ median cell-culture infectious doses of each 
Sabin poliovirus serotype, and any further increases in 
the inoculum might have limited effect.
There was some evidence that additional oral vaccine 
doses were beneficial for OPV in the single eligible study. 
This is consistent with the observation from supple-
mentary immunisation programmes that additional 
doses are immunogenic and that efficacy increases with 
a constant per-dose response rate.48,54 For RVV, we 
observed no significant benefit of giving additional 
Rotarix vaccine (3–5 doses vs 1–3 doses) up until age 
22 weeks. However, RVV studies typically compared a 
schedule of RVV given at age 6, 10, and 14 weeks with 
RVV given at age 10 weeks and 14 weeks (rather than the 
standard schedule given at age 6 weeks and 10 weeks for 
Rotarix), which might explain the lack of benefit 
observed. A booster dose of RVV at age 9 months induced 
IgA seroconversion in more than 40% of Bangladeshi 
infants who had received two previous doses of vaccine,55 
0·5 1·0 4·02·0
Zinc
Vitamin A
RVV separated from OPV
Probiotic
OPV valence
Narrow dose interval
Increase vaccine inoculum
Extra doses
Extra dose at birth
Delayed first dose
Buffer
Breastfeeding withheld
0·5 1·0 4·02·0 0·5 1·0 4·02·0
Anthelmintic
Effect size (relative risk) Effect size (relative risk) Effect size (relative risk)
OCV
Subjects (n)
Studies (n)
1000
500
100
>1
1
RVV OPV
Favours oral vaccine
seroconversion
Favours oral vaccine
seroconversion
Favours oral vaccine
seroconversion
Figure 4: Meta-analysis summary
Summary effect sizes from forest plots for each intervention according to vaccine type (OCV, RVV, and OPV). Error bars represent 95% CI and the size of the circles 
corresponds to the number of participants. OCV=oral cholera vaccine. OPV=oral poliovirus vaccine. RVV=rotavirus vaccine.
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highlighting the potential benefit of additional doses in 
later infancy.
Finally, our meta-analysis showed that a birth dose of 
OPV had no overall effect on seroconversion rates. 
However, these data do not capture the benefits of 
vaccinating at birth to improve coverage.56 Moreover, a 
benefit of vaccination in the neonatal period is protection 
from early natural infection, which occurs frequently in 
low-income countries.57
For most interventions, we found no evidence of effect 
on oral vaccine performance. In the meta-analysis, there 
was no benefit of vitamin A supplementation for OPV 
or OCV immunogenicity in Asia or Africa. We also 
found no overall effect of zinc supplementation on oral 
vaccine responses across five studies, despite its role in 
mucosal protection.58 However, secondary analyses 
showed that zinc supplementation had a greater effect 
on oral vaccine responses among older children. 
Vitamin A and zinc deficiency vary with age and setting, 
and true deficiency might have been under-represented 
in the included trials. Three randomised trials showed 
no effect of temporarily withholding breastfeeding on 
RVV, live-attenuated OCV (CVD 103-HgR), or OPV 
immuno genicity. In one trial in Pakistan, there was, 
paradoxically, weak evidence for increased RVV 
seroconversion rates in the group with liberalised 
breastfeeding.59 Notably, breastfeeding was only 
withheld for short periods (mean 3·2 h); however, the 
feasibility and value of withholding breastfeeding for 
longer is doubtful. Instead, other novel methods such as 
vector systems should be pursued to tackle maternal 
antibody interference.60 The results from our meta-
analysis show no significant benefits overall for 
probiotics, despite findings from individual studies that 
probiotics can increase levels of specific antibodies to 
oral vaccines. This finding might be due to the hetero-
geneity of probiotic strains, reflecting an incomplete 
understanding of which are most likely to confer 
benefits. In a previous systematic review of the effects of 
probiotics on oral and parenteral vaccines, a total of 
40 different probiotics were tested, with variations in 
dose, purity, and timing of administration.18 The review 
concluded that the potential benefit of probiotics was 
strongest for oral vaccines, although only two studies 
were done among children.
Our review highlights several interventions that merit 
further study. First, although we found no overall benefit 
from increasing the number of RVV doses, additional 
doses given at birth or later in infancy may have a greater 
impact, particularly as WHO guidelines now allow 
for later dosing of RVV.61 There is also interest in early 
oral vaccination using neonatal strains of rotavirus. 
One candidate (RV3-BB) was shown to be efficacious 
against severe gastroenteritis in Indonesian infants.62
Second, of the six probiotic studies included in the 
qualitative analysis, four were done in European 
countries and three of these recruited adult participants. 
It is therefore difficult to draw conclusions about the 
value of probiotics in improving oral vaccine efficacy 
among infants in LMICs. Moreover, the association 
between bacterial microbiota composition and oral 
vaccine responses remains equivocal.63 Further studies 
might help to better define microbiota-directed therapies 
that will benefit vaccine efficacy.
Third, we did not find any studies exploring the effects 
of water, sanitation, or hygiene on oral vaccine responses, 
although one study is underway in Zimbabwe.64 
Fourth, no studies investigated adjustments to RVV 
inoculum (with the exception of early pre-licensure 
immunogenicity dose-finding trials, which were 
excluded).65,66 Our search of the grey literature highlighted 
one trial, underway in Bangladesh, exploring the effects 
of an increased inoculum on RVV immunogenicity 
(NCT02992197). Finally, only one antenatal intervention 
trial was identified in this systematic review.26 In this 
study, OPV seroconversion was similar among infants of 
mothers randomised to receive vitamin A or placebo 
in pregnancy. The antenatal period might provide a 
window of opportunity to assess the effect of maternal 
interventions such as macro nutrients, micronutrients, 
probiotics, or antibiotics, since oral vaccine under-
performance occurs so early in infancy.
Our study has several limitations. First, we used 
seroconversion as our primary outcome for meta-
analysis; however, serological markers do not always 
correlate with protection from disease, particularly for 
RVV, for which rotavirus-specific IgA is a poor correlate 
of protection in low-income countries.67 Second, there 
were differences in study design and significant 
heterogeneity between studies for several interventions, 
despite our strict inclusion criteria, probably reflecting 
the range of ages, settings, and vaccine types across 
studies. However, we undertook meta-regression to 
provide insights into factors that drive heterogeneity and 
did sensitivity analyses restricted to studies that 
measured vaccine immunogenicity during a narrow time 
window, which did not change our inferences. Third, 
several studies reported high seroconversion rates in 
intervention and control groups, which might have 
obscured detection of a beneficial treatment effect. For 
example, effect size was negatively correlated with 
background immunogenicity for valence and separation 
of RVV from OPV. Studies with high background 
immuno genicity might also have contributed to the 
potential publication bias observed for several 
interventions because their small effect sizes and 
standard errors might create an apparent skew in funnel 
plots and Egger’s test p values. Finally, comparisons 
often included small numbers of studies, subdivided by 
vaccine type, which were sometimes done among adults 
in high-income countries. Therefore, the available 
evidence was sometimes insufficient to determine the 
generalisability of inter ventions for the most relevant 
populations of interest (mostly infants in LMICs), which 
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is apparent from the substantial proportion of studies 
that were downgraded for indirectness in the GRADE 
assessment.
Oral vaccines provide tremendous benefits in 
developing countries; however, they are failing to reach 
their full potential. Very few strategies substantially 
improve oral vaccine immunogenicity, and those that 
do have modest effects. There is a need to better 
understand the causes of oral vaccine failure to inform 
more effective interventions; however, overcoming the 
multiple factors that probably underlie oral vaccine 
failure in LMICs might be difficult.3 In addition to 
optimising the effectiveness of intervention approaches, 
other factors such as safety, feasibility, and affordability 
should be considered. Immunisation strategies in 
LMICs must therefore also consider alternatives to 
oral vaccines. Bypassing the gut through parenteral 
administration, for example, is an alternative strategy 
not evaluated in this review. In 2018, a Vi-polysaccharide 
tetanus-toxoid conjugate typhoid vaccine received 
WHO pre-qualification, supported by field estimates 
showing long-term protection,68 and a parenteral 
rotavirus vaccine has been shown to be immunogenic 
in South African infants.69 Another strategy being 
explored is the use of mucosal adjuvants such as dmLT, 
a detoxified version of Escherichia coli enterotoxin, 
combined with inactivated poliovirus vaccine.70 
However, whether these interventions can be scaled up 
effectively is unclear. Meanwhile, introducing changes 
in oral vaccine scheduling, such as deferred RVV 
dosing, after a careful assessment of the costs and 
benefits, could improve the effect of oral vaccines for 
children in LMICs countries and reduce the global 
burden of diarrhoeal disease.
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